Analyst Price Targets — AXON
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 8, 2026 12:00 pm | — | Morgan Stanley | $675.00 | $391.53 | TheFly | Morgan Stanley buyers of Axon weakness after underperformance |
| April 8, 2026 11:57 am | — | Goldman Sachs | $625.00 | $391.53 | TheFly | Axon price target lowered to $625 from $720 at Goldman Sachs |
| February 25, 2026 2:24 pm | — | Robert W. Baird | $800.00 | $523.63 | TheFly | Axon price target lowered to $800 from $900 at Baird |
| February 25, 2026 2:16 pm | Jeremy Hamblin | Craig-Hallum | $820.00 | $543.47 | StreetInsider | Axon Enterprise (AXON) PT Lowered to $820 at Craig-Hallum |
| February 25, 2026 1:56 pm | David Paige | RBC Capital | $735.00 | $543.24 | StreetInsider | Axon Enterprise (AXON) PT Lowered to $735 at RBC Capital |
| February 25, 2026 1:41 pm | James Fish | Piper Sandler | $690.00 | $548.23 | StreetInsider | Axon Enterprise (AXON) PT Lowered to $690 at Piper Sandler |
| January 6, 2026 12:04 pm | Keith Housum | Northcoast Research | $742.00 | $591.16 | TheFly | Axon upgraded to Buy from Neutral at Northcoast |
| December 17, 2025 12:43 pm | Meta Marshall | Morgan Stanley | $713.00 | $555.06 | TheFly | Axon price target lowered to $713 from $760 at Morgan Stanley |
| November 17, 2025 9:43 am | — | RBC Capital | $860.00 | $554.37 | TheFly | Axon initiated with an Outperform at RBC Capital |
| November 5, 2025 12:09 pm | James Fish | Piper Sandler | $753.00 | $622.38 | StreetInsider | Axon Enterprise (AXON) PT Lowered to $753; Piper Sandler 'Buying on Pullback' |
Latest News for AXON
Bosman Wealth Management LLC cut its holdings in Axon Enterprise, Inc (NASDAQ: AXON) by 56.1% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 1,809 shares of the biotechnology company's stock after selling 2,315 shares during the quarter. Bosman Wealth Management LLC's holdings in Axon
Chicago Capital LLC increased its holdings in shares of Axon Enterprise, Inc (NASDAQ: AXON) by 24.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 22,145 shares of the biotechnology company's stock after acquiring an additional 4,384 shares during the period. Chicago Capital
Netflix outperformed during the period as investor concerns around a potential acquisition of Warner Bros. Discovery subsided. Microsoft lagged during the quarter despite reporting strong underlying results, as investor focus remained on slightly softer Azure growth and elevated AI-related investment. We believe Alnylam Pharmaceuticals' differentiated platform and growing pipeline position it well for sustained…
Axon Enterprise (AXON) concluded the recent trading session at $393.08, signifying a -2.26% move from its prior day's close.
Zacks.com users have recently been watching Axon (AXON) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.